A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans.
A method to study reverse cholesterol transport in humans was developed using stable isotopes and kinetic analysis. Three normolipidemic subjects received simultaneous intravenous infusions of deuterated leucine and (13)C-acetate for 14 and 8 hours, respectively. Deuterium enrichment was measured in protein-bound leucine in apolipoproteins (apo) B-100 and A-I (using gas chromatography coupled with mass spectrometry [GCMS]) and (13)C-enrichment in unesterified cholesterol and cholesteryl ester (using gas chromatography coupled to isotope ratio mass spectrometry [GC-C-IRMS]) in very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) during the tracer infusion. Curves were analyzed using multicompartmental analysis. This protocol is suitable to quantify the different processes involved in reverse cholesterol transport (RCT) in humans, including cholesterol esterification, transfer of cholesteryl ester from HDL towards apo B-100-containing lipoproteins, and the contribution of VLDL, LDL, and HDL in the final steps of RCT. In agreement with previous data from kinetic analysis of radiotracer experiments, our results suggest that in fasting normolipidemic subjects the major fraction of cholesteryl ester enters plasma through esterification in HDL (more than 95%). The major fraction of cholesteryl ester disappears through apo B-100-containing lipoproteins (VLDL and LDL) catabolism (mean of 82%) rather than through removal from HDL (mean of 18% with approximately an equal part for apo AI-dependent and independent catabolism, respectively, 7% and 11%). We conclude that this protocol could be applied to study the modulation of these processes by nutrition, diseases, or pharmacologic treatments.
Ouguerram
K
K
Centre de Recherche en Nutrition Humaine, INSERM U539, Nantes, France.
Krempf
M
M
Maugeais
C
C
Maugère
P
P
Darmaun
D
D
Magot
T
T
D000085:Acetates / Q000494:pharmacology; D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000032:analysis; D001692:Biological Transport; D002247:Carbon Isotopes; D002784:Cholesterol / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D002788:Cholesterol Esters / Q000097:blood; D003903:Deuterium; D004951:Esterification; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007930:Leucine / Q000097:blood / Q000494:pharmacology; D008074:Lipoproteins / Q000737:chemistry; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000737:chemistry; D008079:Lipoproteins, VLDL / Q000737:chemistry; D008297:Male; D008722:Methods; D008954:Models, Biological; D012016:Reference Values
D000085:Acetates; D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D002247:Carbon Isotopes; D002788:Cholesterol Esters; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D002784:Cholesterol; D003903:Deuterium; D007930:Leucine